Remove Data Remove DEA Remove Patients Remove Pharmaceutical
article thumbnail

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. Drug Enforcement Agency (DEA). “We know cannabis has powerful potential medical effects. territories. This means that U.S.

article thumbnail

‘The most meaningful cannabis reform in decades’: Experts weigh in on new DEA rules

The Cannigma

All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We BRC) told The Cannigma this week. Junk’ cannabis ‘ill-suited for clinical trials’. Shutterstock).

DEA 133
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development

Cannabis Law Report

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. .

DEA 66
article thumbnail

The Epidiolex Effect: Will Other CBD Drugs Receive FDA and DEA Approval?

Freedom Leaf

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. Frontier Data predicts total sales of all CBD products in the U.S. will top $1.9 billion by 2022. John’s wort. will top $1.9

DEA 51
article thumbnail

PHILLIPS LYTLE LLP LAUNCHES PSYCHEDELICS & MENTAL HEALTH THERAPIES PRACTICE

Cannabis Law Report

Among the first in the nation, Phillips Lytle’s Psychedelics Practice Team combines expertise in pharmaceutical science, FDA regulations and risk management to serve the legal needs of emerging bio-tech sectors. “It also creates new opportunities for researchers, entrepreneurs, investors and pharmaceutical companies.

Therapy 52
article thumbnail

MAPS Organization Granted $12.9 Million to Study Cannabis and PTSD •

SpeedWeed

This trial will be the second of its kind to be conducted so far, and one that is an FDA- and DEA-regulated double-blind, placebo-controlled study. Results of this study showed evidence of the pros and cons to cannabis as a treatment for PTSD patients. PTSD affects a large number of military veterans.

article thumbnail

Veriheal’s Innovation in Cannabis Scholarship 2020 Winners

Veriheal

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Program between St. Bonaventure University and George Washington University School of Medicine. . School: University of Maryland.